Isolation and Characterization of Urinary Extracellular Vesicles from Healthy Donors and Patients with Castration-Resistant Prostate Cancer

被引:14
|
作者
Lee, Haneul [1 ]
Kang, Su Jin [1 ]
Lee, Jimin [2 ]
Park, Kyong Hwa [2 ]
Rhee, Won Jong [1 ,3 ,4 ]
机构
[1] Incheon Natl Univ, Dept Bioengn & Nanobioengn, Incheon 22012, South Korea
[2] Korea Univ, Dept Internal Med, Div Oncol Hematol, Coll Med, Seoul 02841, South Korea
[3] Incheon Natl Univ, Div Bioengn, Incheon 22012, South Korea
[4] Incheon Natl Univ, Res Ctr Bio Mat & Proc Dev, Incheon 22012, South Korea
基金
新加坡国家研究基金会;
关键词
liquid biopsy; extracellular vesicle; prognosis; urine; castration-resistant prostate cancer; MICRORNA BIOMARKERS; PROGRESSION; MIRNAS;
D O I
10.3390/ijms23137134
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate cancer (PCa) is the most commonly diagnosed malignancy among men in developed countries. The five-year survival rate for men diagnosed with early-stage PCa is approximately 100%, while it is less than 30% for castration-resistant PCa (CRPC). Currently, the detection of prostate-specific antigens as biomarkers for the prognosis of CRPC is criticized because of its low accuracy, high invasiveness, and high false-positive rate. Therefore, it is important to identify new biomarkers for prediction of CRPC progression. Extracellular vesicles (EVs) derived from tumors have been highlighted as potential markers for cancer diagnosis and prognosis. Specifically, urinary EVs directly reflect changes in the pathophysiological conditions of the urogenital system because it is exposed to prostatic secretions. Thus, detecting biomarkers in urinary EVs provides a promising approach for performing an accurate and non-invasive liquid biopsy for CPRC. In this study, we effectively isolated urinary EVs with low protein impurities using size-exclusion chromatography combined with ultrafiltration. After EV isolation and characterization, we evaluated the miRNAs in urinary EVs from healthy donors and patients with CRPC. The results indicated that miRNAs (miR-21-5p, miR-574-3p, and miR-6880-5p) could be used as potential biomarkers for the prognosis of CRPC. This analysis of urinary EVs contributes to the fast and convenient prognosis of diseases, including CRPC, in the clinical setting.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Emerging treatment options for patients with castration-resistant prostate cancer
    George, Daniel
    Moul, Judd W.
    PROSTATE, 2012, 72 (03): : 338 - 349
  • [32] Food Effects on Abiraterone Pharmacokinetics in Healthy Subjects and Patients With Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Spratlin, Jennifer
    Kollmannsberger, Christian
    North, Scott
    Pankras, Catherine
    Gonzalez, Martha
    Bernard, Apexa
    Stieltjes, Hans
    Peng, Lixian
    Jiao, James
    Acharya, Milin
    Kheoh, Thian
    Griffin, Thomas W.
    Yu, Margaret K.
    Chien, Caly
    Nam Phuong Tran
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (12): : 1406 - 1414
  • [33] MLL translocation in two castration-resistant prostate cancer patients
    Chowdry, Rajasree Pia
    Ledet, Elisa
    Asinghe, Lahiru Ran.
    Sartor, Alton Oliver
    CANADIAN JOURNAL OF UROLOGY, 2016, 23 (05) : 8483 - 8486
  • [34] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
    La, Jennifer
    Wang, Lin
    Corrigan, June K.
    Lang, Deborah
    Lee, Michelle H.
    Do, Nhan V.
    Brophy, Mary T.
    Paller, Channing J.
    Fillmore, Nathanael R.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [35] IMPROVED SURVIVAL PROSPECTS FOR PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
    Kirby, Roger S.
    Fitzpatrick, John M.
    BJU INTERNATIONAL, 2011, 107 (05) : 697 - 700
  • [36] Experience with fulvestrant acetate in castration-resistant prostate cancer patients
    Gasent Blesa, J. M.
    Alberola Candel, V.
    Giner Marco, V.
    Giner-Bosch, V.
    Provencio Pulla, M.
    Laforga Canales, J. B.
    ANNALS OF ONCOLOGY, 2010, 21 (05) : 1131 - 1132
  • [37] Loading of "cocktail siRNAs" into extracellular vesicles via TAT-DRBD peptide for the treatment of castration-resistant prostate cancer
    Diao, Yanjun
    Wang, Gangqiang
    Zhu, Bingbing
    Li, Zhuo
    Wang, Shan
    Yu, Lijuan
    Li, Rui
    Fan, Weixiao
    Zhang, Yue
    Zhou, Lei
    Yang, Liu
    Hao, Xiaoke
    Liu, Jiayun
    CANCER BIOLOGY & THERAPY, 2022, 23 (01) : 163 - 172
  • [38] Isolation and characterization of high-purity invasive CTCs from men with metastatic castration-resistant prostate cancer (mCRPC).
    Premasekharan, Gayatri
    Friedlander, Terence W.
    Ngo, Vy T.
    Gilbert, Elizabeth
    Sathaye, Priya
    Harris, Anna
    Ryan, Charles J.
    Paris, Pamela L.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [39] Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
    Lin, Ting-Ting
    Chen, Ye-Hui
    Wu, Yu-Peng
    Chen, Shao-Zhan
    Li, Xiao-Dong
    Lin, Yun-Zhi
    Chen, Shao-Hao
    Zheng, Qing-Shui
    Wei, Yong
    Xu, Ning
    Xue, Xue-Yi
    JOURNAL OF CANCER, 2019, 10 (22): : 5608 - 5613
  • [40] BIOMARKERS FOR CHARACTERIZATION AND THERAPEUTIC ORIENTATION IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
    Plata Bello, Ana
    Tamayo Jover, Marco Antonio
    Gutierrez Nicolas, Fernando
    Acosta Lopez, Silvia
    Concepcion Masip, Tomas
    Plata Bello, Julio
    ARCHIVOS ESPANOLES DE UROLOGIA, 2022, 75 (02): : 195 - 202